Skip to main content

Table 4 Characteristics of the patients with Chronic Chikungunya arthritis (n = 60)

From: Post-chikungunya arthritis: a longitudinal study in a tertiary care hospital in Bangladesh

Characteristics

All (n = 60)

Preexisting rheumatic disorders

Gender

Absent (n = 52)

Present (n = 8)

Male (n = 26)

Female (n = 34)

Age (in years)

     

 Up to 40

27 (45.0)

23 (44.2)

4 (50.0)

14 (53.8)

13 (38.2)

  > 40

33 (55.0)

29 (55.8)

4 (50.0)

12 (46.2)

21 (61.8)

Women

34 (56.7)

27 (51.9)

7 (87.5)

  

Comorbidity

30 (50.0)

24 (46.1)

6 (75.0)

9 (34.6)

21 (61.8)

No preexisting rheumatic disorders

52 (86.7)

  

25 (96.1)

27 (79.4)

IgG positive

19 (31.7)

16 (30.8)

3 (37.5)

6 (23.1)

13 (38.2)

Type of joint involvement

     

 Only pain

39 (65.0)

34 (65.4)

5 (62.5)

18 (69.2)

21 (61.8)

 Pain with swelling

21 (35.0)

18 (34.6)

3 (37.5)

8 (30.8)

13 (38.2)

Laboratory finding

     

 Anti CCP

1(1.7)

0 (0.0)

1 (1.9)

1 (3.8)

0 (0.0)

 HLA B27

2 (3.4)

1 (1.9)

1 (1.9)

1 (3.8)

1 (2.9)

 Anti CCP + HLA B27

1 (1.7)

1 (1.9)

0 (0.0)

1 (3.8)

0 (0.0)

 RF

2 (3.3)

1 (1.9)

1 (1.9)

1 (3.8)

1 (2.9)

Ultra-sonographic findings

     

 Tenosynovitis

19 (31.7)

19 (36.5)

0 (0.0)

9 (34.6)

10 (29.4)

 Synovial hypertrophy

8 (13.3)

8 (15.4)

0 (0.0)

2 (7.7)

6 (17.6)

 Tendinitis

7 (11.7)

6 (11.5)

1 (1.9)

5 (19.2)

2 (5.9)

 Median nerve entrapment

4 (6.7)

4 (7.7)

0 (0.0)

1 (3.8)

3 (8.8)

 Joint effusion

3 (5.0)

2 (3.8)

1 (1.9)

1 (3.8)

2 (5.9)

 Bursitis

2 (3.3)

2 (3.8)

0 (0.0)

1 (3.8)

1 (2.9)

X-ray finding

     

 Unilateral sacroiliitis

1 (1.7)

0 (0.0)

1 (1.9)

0 (0.0)

1 (2.9)

 Bilateral sacroiliitis

4 (6.7)

4 (7.7)

0 (0.0)

1 (3.8)

3 (8.8)

 Functional disability at one year

(n = 21)

(n = 17)

(n = 4)

(n = 9)

(n = 12)

 Mild

18 (85.7)

15 (28.8)

3 (37.5)

8 (30.8)

10 (29.4)

 Moderate

2 (3.3)

2 (3.8)

0 (0.0)

1 (3.8)

1 (2.9)

 Severe

1 (1.7)

0 (0.0)

1 (1.9)

0 (0.0)

1 (2.9)

  1. Numbers in parentheses indicated percentages. CCP Cyclic citrullinated peptide, HLA-B27 Human leukocyte antigen B27, RF Rheumatoid Factor